About Seebri®/NVA237

Once-daily Seebri® (NVA237) (glycopyrronium bromide; Seebri® Breezhaler® (EU), Seebri® Inhalation Capsules 50mcg (Japan)) is an inhaled long-acting muscarinic antagonist (LAMA) that has already been approved in the EU and Japan as a maintenance bronchodilator treatment for COPD.
In the US, NVA237 was approved in October 2015 as a twice daily inhaled monotherapy for the long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema under the brand name Seebri™ Neohaler® (glycopyrrolate 15.6 mcg).


Milestones and Royalty Revenue

Under the terms of the agreement with Novartis, Sosei is eligible to receive Seebri® development milestones and fixed-rate royalties on worldwide product sales.

Related material


About COPD (chronic obstructive pulmonary disease)

COPD is a chronic obstruction of the airways caused by emphysema or chronic bronchitis induced primarily by smoking or air pollution.
According to a WHO survey, there were 210 million COPD patients worldwide in 2009, and in 2012, COPD became the third leading cause of death.

COPD market

In 2013, the COPD market was estimated at around $13 billion. It is expected to increase still further in future, reaching $19 billion by 2019 as a result of better recognition of the disease and improved treatment options.


Seebri® Breezhaler® and Seebri® Inhalation Capsules 50mcg are registered trademarks of Novartis AG.